Beyfortus (Nirsevimab) is Superior to Synagis (Palivizumab) for RSV Prophylaxis
Beyfortus is the better choice because it requires only a single dose per RSV season compared to Synagis's monthly injections, provides protection for all infants rather than just high-risk groups, and offers equivalent efficacy with dramatically improved convenience and broader population coverage. 1, 2
Key Advantages of Beyfortus Over Synagis
Single-Dose vs. Monthly Administration
The most clinically significant advantage is dosing frequency. Beyfortus requires only one intramuscular injection per RSV season, while Synagis demands monthly injections throughout the entire RSV season (typically 5 months). 1, 2 This single-dose regimen:
- Eliminates the burden of repeated clinic visits
- Reduces cumulative injection-related adverse events
- Improves adherence and ensures complete seasonal protection
- Allows administration during birth hospitalization 1
Universal vs. Restricted Population Coverage
Beyfortus is FDA-approved and ACIP-recommended for ALL infants <8 months entering their first RSV season, regardless of risk factors. 1 In stark contrast, the American Academy of Pediatrics restricts Synagis to only high-risk infants (comprising <5% of all infants) with specific medical conditions such as:
- Extreme prematurity (≤30 weeks gestation)
- Hemodynamically significant heart disease
- Chronic lung disease
This is critical because 79% of infants hospitalized with RSV have no underlying medical conditions. 1 Synagis's restricted indication leaves the vast majority of at-risk healthy term infants unprotected, while Beyfortus addresses this gap.
Comparable Efficacy
When accounting for differences in study populations and endpoint definitions, both agents demonstrate broadly comparable protection against severe RSV disease. 3 Meta-analyses show palivizumab reduces medically attended RSV infections by 70.5% in preterm infants, with broadly similar efficacy to nirsevimab. 4 Real-world effectiveness data for nirsevimab demonstrates 80.9% protection against RSV-associated hospitalization. 5
Safety Profile
Both agents show favorable and comparable tolerability profiles. 3 Post-marketing surveillance reveals distinct adverse event patterns, but both remain safe. 6 Beyfortus can be safely co-administered with routine childhood vaccines. 1, 2
Practical Implementation
Dosing Algorithm for Beyfortus
First RSV Season:
- <5 kg body weight: 50 mg single IM injection
- ≥5 kg body weight: 100 mg single IM injection 2
Second RSV Season (high-risk children up to 24 months):
- 200 mg administered as two 100 mg injections regardless of weight 2
Timing Considerations
- Administer October through March in most continental U.S. locations 1
- Infants born during RSV season: give within 1 week of birth
- Infants born outside RSV season: give shortly before season onset 1, 2
Critical Caveat: Transition from Synagis
Do not administer Synagis to infants who have already received Beyfortus in the same season. 2 However, Beyfortus may be given to children who received Synagis in their first RSV season when entering their second season. 2 There are no data supporting substitution of Beyfortus for Synagis mid-season once prophylaxis with Synagis has been initiated. 2
Cost-Effectiveness and Access
While Synagis use is limited by high cost and monthly dosing requirements 1, Beyfortus's single-dose regimen and broader indication make it more practical for universal infant immunization programs. The cost-effectiveness improves when considering reduced hospitalizations across the entire infant population rather than just the 5% eligible for Synagis.
The evidence unequivocally supports Beyfortus as the preferred agent for RSV prophylaxis in 2023 and beyond, with Synagis now relegated to historical significance after 28 years of use. 1, 3